# Evaluating Tocilizumab for Sever COVID-19 Infection in Breast Cancer vs. Non Cancer Pateints

> **NCT04871854** · PHASE2 · COMPLETED · sponsor: **Beni-Suef University** · enrollment: 100 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Tocilizumab
- **DRUG:** traditional Covid -19 therapy

## Key facts

- **NCT ID:** NCT04871854
- **Lead sponsor:** Beni-Suef University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-04-26
- **Primary completion:** 2022-07-26
- **Final completion:** 2022-08-26
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2022-11-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04871854

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04871854, "Evaluating Tocilizumab for Sever COVID-19 Infection in Breast Cancer vs. Non Cancer Pateints". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04871854. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*